Maravai LifeSciences Holdings Inc. Class A Common Stock vs Ulta Beauty Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Ulta Beauty Inc trades at $595.81 (market cap $25.33B). The key difference: Ulta Beauty Inc is far larger — about 25.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ulta Beauty Inc is more actively traded (603,913 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Ulta Beauty Inc for 92 Days on average.
| MRVI | ULTA | |
|---|---|---|
Market Cap | $977.37M | $25.33B |
Volume | 2,742,564 | 603,913 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $706.82 |
52-Week Low | $2.83 | $450.75 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $1.08B | $27.64B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
ULTA trades at $579.00, up 2.03% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $624.93. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 outlook, driven by e-commerce momentum. Revenue reached $11.30 billion in 2025, though net margin dipped to 9.34%. The stock shows strong profitability with a 46.12% ROE, but faces margin pressure and flat store traffic.
The stock offers upside to analyst targets with solid growth prospects in wellness and omnichannel expansion, but risks include consumer spending volatility, promotional pressures, and insider selling. Execution on raised guidance and margin stability are key for sustained gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →